Affective Disorders, Bone Metabolism, and Osteoporosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General; 2004, WE 225 B71259 2004.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.
Eaton WW, editor. Medical and psychiatric comorbidity over the lifecourse. Arlington, VA: American Psychiatric Publishing Inc; 2005.
Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diab Care. 2008;31:2383–90.
Van der Kooy K, van Hout H, Marwijk H, et al. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psych. 2007;22:613–26.
Halbreich U. Osteoporosis, schizophrenia, and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641–57.
Cizza G, Ravn P, Chrousos G. Depression: a major, unrecognized risk factor for osteoporosis? Trend Endocrinol Metab. 2001;12:198–203.
Murray CJ, Lopez AD. Global burden, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349:1436–42.
Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psych. 1993;54:405–18.
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.
Eaton WW, Kalaydjian A, Scharfstein DO, et al. Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981–2004. Acta Psych Scand. 2007;116:182–8.
Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psych. 2008;65:513–20.
American Psychiatric Assocation. Diagnostic and statistical manual of mental disorders—IV. Washington, DC: American Psychiatric Association; 1994.
Schweiger U, Deuschle M, Körner A, et al. Low lumbar bone mineral density in patients with major depression. Am J Psych. 1994;151:1691–3.
Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int. 2008;19:1–12.
Whooley MA, Cauley JA, Zmuda JM, et al. Depressive symptoms and bone mineral density in older men. J Geriatr Psych Neurol. 2004;17:88–92.
Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Arch Intern Med. 1999;159:484–90.
Reginster JY, Deroisy R, Paul I, et al. Depressive vulnerability is not an independent risk factor for osteoporosis in post-menopausal women. Maturitas. 1999;33:133–7.
Robbins J, Hirsch C, Whitmer R, et al. The association of bone mineral density and depression in an older population. J Am Geriatr Soc. 2001;49:732–6.
Yazici AE, Bagis S, Tot S, et al. Bone mineral density in premenopausal women with major depression. Joint Bone Spine. 2005;72:540–3.
Yazici K, Akinci A, Sütçü A, et al. Bone mineral density in premenopausal women with major depressive disorder. Psych Res. 2003;117:271–5.
Jacka FN, Pasco JA, Henry MJ, et al. Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis study. Menopause. 2005;12:88–91.
Wong SY, Lau EM, Lynn H, et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Osteoporos Int. 2005;16:610–5.
Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. NEJM. 1996;335:1176–81.
Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329–36.
Amsterdam JD, Hooper MB. Bone density measurement in major depression. Prog Neuropsychopharmacol Biol Psych. 1998;22:267–77.
Petronijević M, Petronijević N, Ivković M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone. 2008;42:582–90.
Mezuk B, Eaton WW, Golden SH, et al. Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci. 2008;63:1410–5.
Schweiger U, Weber B, Deuschle M, et al. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psych. 2000;157:118–20.
Søgaard AJ, Joakimsen RM, Tverdal A, et al. Long-term mental distress, bone mineral density, and non-vertebral fractures. Osteoporos Int. 2005;16:887–97.
Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23:567–74.
Milliken LA, Wilhelmy J, Martin CJ, et al. Depressive symptoms and changes in body weight exert independent and site-specific effects on bone in postmenopausal women exercising for 1 year. J Gerontol A Biol Sci Med Sci. 2006;61A:488–94.
Takkouche B, Montes-Martinez A, Gill S, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Safety. 2007;30:171–84.
Kessler RC, Berglund P, Delmer O, et al. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psych. 2005;62:593–602.
Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psych. 2002;59:530–7.
Vestergaard P. Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics. Curr Drug Saf. 2008;3:185–9.
Raisz L. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999;48:1353–8.
Williams LJ, Pasco JA, Jacka FN, et al. Depression and bone metabolism. Psychother Psychosom. 2009;78:16–25.
Licinio J, Wong M. The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-response systems, and contribute to neurotoxicity and neuroprotection. Mol Psych. 1999;44:317–27.
Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Internal Med. 1998;128:127–37.
De Berardis D, Campanella D, Gambi F, et al. The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol. 2006;19:721–5.
Herrán A, Amado JA, García-Unzueta MT, et al. Increased bone remodeling in first-episode major depressive disorder. Psychosom Med. 2000;62:779–82.
Kiecolt-Glaser J, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53:873–6.
Mommersteeg PM, Vermetten E, Kavelaars A, et al. Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology. 2008;33:1041–50.
Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms in monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med. 2003;65:362–8.
Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun. 2002;16:544–56.
Galliera E, Locati M, Mantovani A, et al. Chemokines and bone remodeling. Int J Immunopathol Pharmacol. 2008;21:485–91.
Kann P, Laudes M, Piepkorn B, et al. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin Rheumatol. 2001;20(1):25–9.
Reynolds RM, Dennison EM, Walker BR, et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif Tissue Int. 2005;77:134–8.
Dennison E, Hindmarsh P, Fall C, et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab. 1999;84:3058–63.
Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med. 1976;6(1):43–50.
Watson S, Gallegher P, Ritchie J, et al. Hypothalamic–pituitary–adrenal axis function in patients with bipolar disorder. Br J Psych. 2004;184:496–502.
Delany AM, Gabbitas BY, Canalis E. Cortisol down-regulates osteoblast procollagen MRNA by transcriptional and post-transcriptional mechanisms. J Cell Biol. 1995;57:488–94.
Bjorntorp P, Rosmond R. The metabolic syndrome—a neuroendocrine disorder? Br J Nutr. 2000;83:S49–57.
Pasquali R, Cantobelli S, Casimirri F, et al. The hypothalamic–pituitary–adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab. 1993;77(2):341–6.
Ljung T, Andersson B, Bengtsson B, et al. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose–response study. Obesity Res. 1996;4:277–82.
Francucci CM, Pantanetti P, Garrapa GG, et al. Bone metabolism and bone mass in women with Cushing’s Syndrome and adrenal incidentaloma. Clin Endrocrinol. 2002;57:587–93.
De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 2008;99:23–43.
Lake CR, Pickar D, Ziegler MG, et al. High plasma norepinephrine levels in patients with major affective disorder. Am J Psych. 1982;139:1315–8.
Maes M, Vandewoude M, Schotte C, et al. Positive relationship between the catecholaminergic turnover and the DST results in depression. Psychol Med. 1990;20(3):493–9.
Brown GW, Harris TO, Eales MJ. Aetiology of anxiety and depressive disorders in an inner-city population. Psychol Med. 1993;23:155–65.
Yirmiya R, Goshen I, Bajayo A, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci USA. 2006;103:16876–81.
Marenzana M, Chenu C. Sympathetic nervous system and bone adaptive response to its mechanical environment. J Musculoskelet Neuronal Interact. 2008;8:111–20.
Shoback D, Marcus R, Bikle D. Chapter 8: metabolic bone disease. In: Greenspan F, Gardner D, editors. Basic and clinical endocrinology. New York: Lange Medical Books/McDraw-hill; 2004. p. 295–361.
Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266–74.
Markopoulou K, Papadopoulos A, Juruena MF, et al. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology. 2009;34:19–26.
Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone. 2001;29:90–5.
Lormeau C, Soudan B, d Herbomez M, et al. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone. 2004;34:933–9.
Battaglino R, Vokes M, Schulze-Späte US. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem. 2007;100:1387–94.
Jankowski CM, Gozanski WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endrocrinol Metab. 2006;91:2986–93.
Jankowski CM, Gozanski WS, Kittelson JM, et al. Increases in bone mineral density in response to oral dehydroandroepisterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endrocrinol Metab. 2008;93:4767–73.
Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083–91.
Kahl KG, Greggersen W, Rudolf S, et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med. 2006;68:669–74.
Altindag O, Altindag A, Asoglu M, et al. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int J Clin Pract. 2007;61:416–20.
Kavuncu V, Kuloglu M, Kaya A, et al. Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med J. 2002;43:101–8.
Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57:485–91.
Grant B, Harford T. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39:197–220.
Chakkalakal DA. Alcohol-induced bone loss and deficient bone repair. Alcohol Clin Exp Res. 2005;29:2077–90.
Peris P, Guañabens N, Monegal A, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;34:936–41.
Holbrook TL, Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. BMJ. 1993;306:1506–9.
Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol. 1995;142:485–92.
Feskanich D, Korrick SA, Greenspan SL, et al. Moderate alcohol consumption and bone density among postmenopausal women. J Womens Health. 1999;8:65–73.
Anda RF, Williamson DF, Escobedo LG, Remington PL, et al. Depression and the dynamics of smoking: a national perspective. JAMA. 1990;264:1541–5.
Breslau N, Kilbey M, Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psych. 1991;48:1069–74.
Kapoor D, Jones T. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol. 2005;152:491–9.
Centers for Disease Control and Prevention. Current trends differences in the age of smoking initiation between blacks and whites. MMWR Morb Mortal Wkly Rep. 1991;40:754–757.
Oncken C, Prestwood K, Kleppinger A, et al. Impact of smoking cessation on bone mineral density in postmenopausal women. J Womens Health. 2006;15:1141–50.
Dargent-Molina P, Poitiers F, Breart G. In elderly women weight is the best predictor of a very low bone mineral density: evidence from the EPIDOS study. Osteporos Int. 2000;11:881–8.
Blouin K, Nadeau M, Mailloux J, et al. Pathways of adipose tissues androgen metabolism in women: depot differences and modulation by adipogenesis. Am J Physiol Endocrinol Metab. 2008;296:244–55.
Kadow-Romacker A, Hoffmann JE, Duda G, et al. Effect of mechanical stimulation on osteoblast- and osteoclast-like cells in vitro. Cell. Tissues Organs. 2008. doi: 10.1159/000178022 .
Lawlor DA, Hart CL, Hole DJ, et al. Body mass index in middle life and future risk of hospital admission for psychosis or depression: findings from the Renfrew/Paisley study. Psycholl Med. 2007;37:1151–61.
Ahlberg AC, Ljung T, Rosmond R, et al. Depression and anxiety symptoms in relation to anthropometry and metabolism in men. Psych Res. 2002;112:101–10.
Schiff I. Principles and practice of endocrinology and metabolism. Menopause. Philadelphia, PA: J.B. Lippincott Company; 1995. p. 915–24.
WHO. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: Report of the WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–126.
Camancho T, Roberts R, Lazarus N, et al. Physical activity and depression: evidence from the Alameda County Study. Am J Epidemiol. 1991;134(2):220–31.
Kritz-Silverstein D, Barrett-Connor E, Corbeau C. Crosssectional and prospective study of exercise and depressed mood in the elderly: the Rancho Bernardo Study. Am J Epidemiol. 2001;153:596–603.
McKercher CM, Schmidt MD, Sanderson KA, et al. Physical activity and depression in young adults. Am J Prev Med. 2009;36:161–4.
Adami S, Gatti D, Viapiana O, et al. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int. 2008;83:388–92.
Korpelainen R, Korpelainen J, Heikkinen J, et al. Lifelong risk factors for osteoporosis and fractures in elderly women with low body mass index—a population-based study. Bone. 2006;39:385–91.
Zerwekh JE, Ruml LA, Gottschalk F, et al. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res. 1998;13:1594–601.
Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitors use by older men. Arch Intern Med. 2007;167:1246–51.
Warden SJ, Haney EM. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: Evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact. 2008;8:121–32.
Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteporos Int. 2005;16:1525–37.
Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167:1240–5.
Szulc P, Munoz F, Marchand F, et al. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men; the MINOS study. Calcif Tissue Int. 2003;73:520–30.
Petty SJ, O’Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteporos Int. 2007;18:129–42.
Misra M, Papakostas G, Klibanksi A. Effect of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psych. 2004;65:1607–18.
O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22:70–5.
Scheen AJ, De Hert MA. Abnormal glucose metabolism is patients treated with antipsychotics. Diab Metab. 2007;33:169–75.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007;18:427–44.
Mak TW, Shek CC, Chow CC, Wing YK, Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab. 1998;83:3857–9.
Depp C, Ojeda VD, Mastin W, et al. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001–2004. Psychiatr Serv. 2008;59:1169–74.
Laroche ML, Charmes JP, Nouaille Y, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63:177–86.
Benton T, Staab J, Evans DL. Medical co-morbidity in depressive disorders. Ann Clin Psych. 2007;19:289–303.
Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and type 2 diabetes. Calcif Tissue Int. 2009;84:45–55.
Lim LS, Fink HA, Kuskowski MA, et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporosis Fractures in Men Study. Arch Intern Med. 2008;168:735–40.
McDonough AK, Rosenthal RS, Cao X, et al. The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 2008;4:507–13.
Plenge P, Rafaelsen OJ. Lithium effects on calcium, magnesium, and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psych Scand. 1982;66:361–73.
Nordenström J, Elvius M, Bågedahl-Strindlund M, et al. Biochemical hyperparathyroidism and bone mineral status in patients treated with long-term lithium. Metabolism. 1994;43:1563–7.
Cohen O, Rais T, Lepkifker E, et al. Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res. 1998;30:594–7.
Gyulai L, Jaggi J, Bauer MS, et al. Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder. Biol Psych. 1997;41:503–6.
Gyulai L, Bauer M, Garcia-Espana F, et al. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term l-thyroxine augmentation. J Affect Disord. 2001;66:185–91.